The practice has been leading research into the devastating disease since 2012 and has collated information on all confirmed cases across the country.
The disease, which originally appeared in the late 1980s, was first detected in the UK in 2012.
When it affects the kidneys, it has a 90% mortality rate.
The new site offers advice and information, including a live map of confirmed cases across the UK, for both vets and pet owners.
David Walker, American, RCVS and EBVS European specialist in small animal internal medicine, leads the team at Anderson Moores and is the UK’s foremost authority on the disease.
He said: “We have been at the forefront of research into CRGV for almost a decade now and have witnessed first-hand the often-devastating effects of the disease.
“In launching this new website, we aim to inform pet owners and colleagues in the veterinary industry about CRGV.
“We hope the confirmed case map will prove useful.
"Although an environmental trigger has not been definitively proven, the seasonality of the disease makes it eminently possible and the map allows everyone to see the location of confirmed cases.”
So far this year, Anderson Moores has recorded a total of 26 confirmed cases of CRGV.
This number comes on the back of 47 confirmed cases during 2020, 19 cases in 2019 and 18 in 2018.
277 cases have been confirmed since the disease was first recognised in the UK in 2012.
David said: “As we enter the winter months, we want to advise dog owners around the country to remain calm but vigilant and seek advice from their local vets if their dog develops an unexplained skin lesion(s), especially on the leg.
“Unfortunately, we find ourselves in the time of year when cases are most commonly identified – 92% of dogs with the disease are seen between November and May.
"This is understandably a concern for dog owners; however, the disease remains rare.
“If a dog is suspected to be suffering from CRGV, the best chance of recovery probably lies with early and intensive management which may be best provided at a specialist facility.
“Treatment primarily revolves around intensive management of the acute kidney injury and is sadly only successful in around 10% cent of cases.”
Visit https://www.alabama-rot.co.uk .
VetSurgeon members Ian and Gillian Mostyn, and the team at Pennine Vets are doing the Coniston Challenge later this year: 30kms of arduous cycling, hiking and canoeing for Guide Dogs.
You can support them with a donation, however small (£2 minimum) at: http://www.justgiving.com/penninevetschallenge.
The small animal and business meeting takes place on the 2nd and 3rd October. The farm and business national meeting is on the 18th and 19th September, and the equine and business meeting is on the 9th and 10th October.
The small animal meeting will also cover other topics such as the art of conversations to dentistry, while the farm meeting will focus on team working, competitive advantage, genomics and mental resilience.
All three events include a team-based activity and a social evening which offers the chance to network and exchange experiences and ideas.
Susan Goodfellow, the Chief Marketing Officer at XLVets said: "It's fine to know what we do but to actually experience it as part of our community is quite different. We know that talking to members and being part of a group of individuals that come together to determine their own future is the best way for veterinary professionals to see what's possible and how we strive for excellence together."
XLVets is also encouraging anyone who is thinking about starting their own practice to attend the events; the company has a number of programmes designed to support prospective owners with things like finding funding, identifying the right financial set up, and acquiring the skills needed to lead a team effectively.
Susan says many vets have a strong entrepreneurial mindset but lack support or know-how to allow them to take the first step to ownership: "Locum roles and mobile set ups are often stepping stones to practice ownership but the barriers can seem significant, not to mention any personal reservations people might have about all it entails. Support from like-minded colleagues who can openly share their experiences can help to make it seem possible, desirable and achievable."
Veterinary professionals wishing to attend one of the meetings should contact Colm McGinn, Chief of Implementation, in confidence, at colm.mcginn@xlvets.co.uk or call 01228 711788.
The updated indications reflect the recognition that Stelfonta may be used in any case where surgery may not be an option:
For the treatment of non-metastatic (WHO staging) mast cell tumours that are either non-resectable or those that are resectable but where surgery is not considered the best option, specifically: cutaneous mast cell tumours (located anywhere on the dog) and subcutaneous mast cell tumours located at or distal to the elbow or the hock.
Tumours must be less than or equal to 8 cm 3 in volume, and must be accessible to intratumoral injection.
Neil Mottram MRCVS, Technical Manager at Virbac said: “Stelfonta offers veterinary surgeons a medical option for the successful elimination of mast cell tumours.
"The extended labelled indication demonstrates the wide variety of cases that can benefit where medical treatment is preferred, such as; tumour factors (location and size) making surgical margins difficult, patient factors (concurrent disease and risk of anaesthesia), clinic factors and the simplification of this medical treatment and owner factors, where there is a preference to avoid surgery."
Stelfonta is administered by injection directly into the tumour mass and Virbac say that generally, dogs do not require sedation or local or general anaesthesia during treatment.
The active ingredient, Tigilanol tiglate, works largely through specific protein kinase c (PKC) activation, in which it locally stimulates the immune system, resulting in destruction of the tumour and the tumour’s blood supply, followed by rapid healing of the site with minimal scarring.
www.virbac.co.uk
Zoetis says the Vetscan OptiCell represents a significant leap forward in technology and offers meaningful time, cost and space savings for veterinary healthcare teams, contributing to better patient outcomes and a more efficient clinic workflow.
It uses cell-focusing and AI-powered classification technology for CBC analysis, delivering a claimed lab quality accuracy at the point of care.
Dr. Richard Goldstein, DVM, DACVIM, DECVIM-CA, Global Chief Medical Officer and Head of Medical Affairs at Zoetis said: “Vetscan OptiCell delivers high-quality results, enables improved efficiency, and provides a compact footprint.
"For the first time, we are able to use advanced AI image recognition technology to characterise the blood cells instead of relying on their size or other physical parameters.”
Pre-orders will be available in the UK later this year.
Virbac Animal Health has announced that registrations on BackHome BioTec, the company's microchip identification service, were moved to the Petlog Database with effect from Monday 12 September 2011.
Virbac says it moved to the UK's largest independent microchip registration database in order to offer an enhanced level of service and support, both to veterinary staff and pet owners.
Practices using the BackHome BioTec system are being asked to log onto www.virbacbackhome.co.uk to create a new account.
Gillian Brown, Product Manager for BackHome at Virbac, said: "BackHome has established itself as a popular, cost-effective and easy to use microchipping system. We believe that in appointing Petlog to manage our registrations we will now be offering a 'best of breed' service for veterinary staff and pet owners.
"We're extremely grateful to Celia Walsom, Petlog Executive, and her team. They have demonstrated unfailing energy, expertise and total dedication to ensuring this move has run smoothly and effectively for all our customers. I am confident that they will benefit from Petlog's commitment to provide a comprehensive identification service which is easy, convenient and secure to use.
"All our existing customers need to do is go to the new website (www.virbacbackhome.co.uk/) and set up an account - it's a simple and quick process. We'll also be providing a range of promotional materials to help them communicate the change to their own clients."
Petlog is owned and managed by the Kennel Club. Virbac says it is fully data compliant and defers income to ensure it can honour its lifetime promise to pet owners. Its Lost and Found helpline is available 24/7, 365 days a year and it is also a founder member of the European Pet Network.
Further information on BackHome BioTec is available on the new website, which also contains a direct link to Petlog.
For further information about BackHome BioTec, please contact your Virbac Territory Manager or call the company on 01359 243243.
CEVA Animal Health has launched a double-sized version of Cyclo Spray, the company's chlorotetracycline-based treatment for the clinical symptoms of foot rot in sheep and digital dermatitis in cattle.
CEVA says that Cyclo Spray's superior spray performance makes it very cost-effective: the aerosol generates a narrow, condensed spray with limited dispersion for accurate application and minimal drip. The spray adheres cleanly and dries fast on the treatment area, to ensure that the antimicrobial has maximum efficacy within the shortest possible spray time.
CEVA adds that each spray of Cyclo Spray covers the skin with a concentration of chlorotetracycline that is thousands of times greater than is actually required to kill the causative bacteria.
The original size can is also available if required.
For further information contact CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG.
Defra has announced that new rules on pet travel will be introduced from 1st January 2012. The changes will mean that the rules on rabies vaccination for entry into the UK will be in line with the rest of Europe.
Defra has carried out a risk assessment to find out how the changes will affect the level of risk of rabies entering the UK. Although the probability of rabies introduction into the UK will increase, the assessment found the risk will remain very low after the increase.
The British Veterinary Association and the British Small Animal Veterinary Association are informing their members of the new rules so that the right advice can be given to pet owners planning to travel abroad with their animals.
Dogs, cats and pet ferrets entering the UK from an EU or 'listed' third country from 1 January 2012 must:
The current requirement to carry out a blood test followed by a six-month wait before entry into the UK will no longer be required.
From 1st January pets entering from a non-listed third country must pass a blood test 30 days after vaccination followed by a three-month wait.
Until now, the UK, Ireland and three other Member States have had derogations from EU pet travel rules to allow for additional controls to protect against rabies, ticks and tapeworms.
Successful vaccination programmes in wildlife in mainland Europe have now allowed the UK to consider whether the additional controls for rabies are still necessary.
The BVA and BSAVA have continued to lobby in Europe for additional controls to be maintained for tapeworms, which could introduce Echinococcus multilocularis to the UK - a significant public health concern.
Although a final decision has not yet been made the European Commission has indicated that it will support the UK case for additional tapeworm controls.
Harvey Locke, President of the BVA, said: "It is vital that any controls on animal movements are proportionate to the risk.
"Due to the highly successful vaccination programme in wildlife in mainland Europe there has been a huge reduction in the incidence in rabies. Research carried out by Defra reveals that the risk of introducing rabies under the new rules is very low.
"However, it is essential that pet owners get good veterinary advice when planning to take their animals abroad because pets can be exposed to a number of diseases not currently endemic in the UK, for example leishmaniasis, babesiosis, and ehrlichiosis.
"As part of responsible ownership we would always advise pet owners to visit their vet for a pre-travel consultation to discuss how to protect the health and welfare of their animals when travelling abroad."
Andrew Ash, President of the BSAVA, added: "The Pet Travel Scheme has been highly successful in keeping the UK free of rabies. BVA and BSAVA have been working closely with Defra to ensure that any changes to the pet travel rules do not threaten our disease-free status.
"The rabies vaccine has advanced and now has a longer duration of immunity and we welcome the continuing requirement for all pets to be vaccinated before travel."
Hill's Pet Nutrition has highlighted recent studies which, the company says, prove that feeding a food enriched with omega-3 fatty acids from fish oils to dogs with osteoarthritis results in a reduction in NSAID dosage of up to 25%1, owner observed improvements in clinical signs3, and improved weight bearing ability2, 7
The claim that food can effectively support medical treatment follows in the wake of two published and one in press study in the Journal of the American Veterinary Medicine Association (JAVMA). These demonstrate that omega-3 enriched food (in this case Hill's Prescription Diet j/d Canine) has significant effects on weight bearing and helps reduce NSAID dosage by up to 25 per cent, when fed to dogs with osteoarthritis 1, 2,3.
According to Hill's, the research demonstrates that in dogs the high levels of eicosapentaenoic acid (EPA) from fish oils can down-regulate the cartilage degrading enzyme aggrecanase1. In vitro studies have also identified that EPA resulted in a reduction in the amount of degraded cartilage residue produced4. High levels of omega-3 fatty acids can also help to reduce inflammation5,6.
The two studies that were recently published confirm that feeding a diet rich in omega-3 fatty acids aids in the management of osteoarthritis in dogs2,3. The randomized double-blinded controlled trials were carried out over three and six months respectively and involved a total of 165 dogs identified as suffering from mild to moderate osteoarthritis. After collating the results from almost 25,000 trial days, researchers were able to confirm a significant 'clinical improvement' from feeding a food fortified with fatty acids.
In the first study described in JAVMA, researchers found evidence that omega-3 fatty acids from fish oils resulted in improvements in weight bearing2. Objective measurement using force plate gait analysis demonstrated that dogs fed a test food fortified with fatty acids were seven times as likely to show improved weight bearing compared with dogs fed a control food.
In the second study, through a detailed questionnaire, owners also observed significant improvements in their dog's osteoarthritic condition3. Improvements observed covered the following signs: difficulty in rising from rest, limping, stiffness, soreness when touched, yelping or whimpering in pain, aggression, lagging on walks, reluctance to play and overall activity level.
Adrian Pratt, Veterinary Affairs Manager for Hill's Pet Nutrition, manufacturer of Prescription Diet j/d, which is enriched with omega-3 fatty acids, hailed the results as a breakthrough in the field of nutrigenomics (the study of the effects of nutrition on gene expression): "This research points the way to a new model for the management of osteoarthritis, using a clinically proven food to interrupt the cycle of damage and cartilage degradation, alongside graded levels of NSAIDs and proactive programmes to manage weight and adjust exercise routines. Clinicians now have the conclusive proof they need to recommend feeding omega-3 enriched food to ameliorate the signs of osteoarthritis in clients' pets and to adjust NSAID doses accordingly."
For further information on Hill's Prescription Diet j/d, please contact your Hill's Territory Manager or call 0800 282438.
References1. A multicenter study of the effect of a therapeutic food supplemented with fish oil omega-3 fatty acids on the Carpofen dosage in dogs with osteoarthritis. Fritsch A, Allen T, Dodd C, JAVMA in press2. Evaluation of the effects of dietary supplementation with fish oil omega-3 fatty acids on weight bearing in dogs. Roush J, Cross A, Renberg W, Dodd C, Sixby K, Fritsch A, Allen T, Jewell, Richardson D, Leventhal P, Hahn K, JAVMA Vol 236 No 1, Jan 2010 pp67-733. Multicenter veterinary practice assessment of the effects of omega-3 fatty acids on osteoarthritis in dogs. Roush J, Dodd C, Fritsch A, Allen T, Jewell D, Schoenherr W, Richardson D, Leventhal P, Hahn K, JAVMA Vol 236 No 1, Jan 2010 pp 59-664. Eicosapentaenoate supplementation abrogates canine articular cartilage degeneration in in vitro explant culture systems, Caterson B, Cramp J, Little C B et al, Hills European Symposium on osteoarthritis and joint health 2005 14-195. Dietary modification of inflammation with lipids, P C Calder, Proceedings of the Nutrition Society 2002 345-3586. Dietary polyunsaturated fatty acids and inflammatory mediator production, James M J, Cleland L G, Gibson R A, Am J Clin Nut 2000: 71 suppl 343S- 358S7. Vasseur PB, Johnson AL, Budsberg SC, et al. Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal anti-inflammatory drug, in the treatment of osteoarthritis in dogs. J Am Vet Med Assoc 1995; 206 (6): 807-811.
Davies Veterinary Specialists (DVS) has announced that it has completed development work on its premises in Higham Gobion, Hertfordshire, to improve capacity and workflow for diagnostic procedures including MRI, CT and endoscopy.
The new development includes the construction and outfitting of an anaesthesia induction room with two state-of-the art stations, a diagnostic imaging viewing room, a further ultrasound and procedures room and office space for the nurse supervisor team. The rooms were built inside the site’s central barn as the next phase of DVS’s ongoing expansion programme, which has recently seen the completion of a new staff room and upgraded kennels and cattery facilities.
Clive Elwood, Managing Director of DVS said: “We first acquired the barn space in 2004 and initial construction included MRI and CT rooms with the plan of completing further rooms as needs arose. This latest development has already had a big impact on workflow and allows us to optimise the use of our diagnostic equipment. It represents our continued commitment to growth and development so that we can serve our customers to the best of our ability. I am very grateful to all of those who contributed to the project and showed necessary patience during construction.”
DVS now employs more than 35 specialist clinicians, 60 nurses, many with an advanced nursing qualification, and 30 administrators and support staff.
For further information visit www.vetspecialists.co.uk. You can also follow DVS on Facebook at http://www.facebook.com/DVSvets.
Ceva says CLAS vials are proven to be easy to use, practical and eco-friendly and are preferred by 99% of farmers on farm1. They have 33% less impact on the environment from cradle to grave than glass2 and are robust and shock resistant3 for fewer breakages and losses. They are made from a lightweight material to make the vials easier to be transported and handled4 and have an ergonomic ‘grip groove’ for easier handing5.
Peter Keyte, ruminant business unit manager at Ceva Animal Health said: "Ceva’s CLAS vials are hugely popular with both vets and farmers due to their practicality, ease of use and environmental credentials.
“We are therefore delighted that Ketofen has joined the extensive range of livestock injectables available in CLAS.”
For further information contact your local Ceva territory manager, call Ceva on 01494 781510 or email cevauk@ceva.com.
References
The BSAVA reports that its Certificates in Medicine and Surgery have sold out in less than 5 minutes, beating the previous record of 20 minutes in their first year.
The Association says that whilst this is testament to the success and demand for its CPD, it is determined to find a way to avoid disappointing so many aspiring students - and after emergency talks over the weekend has decided to run a second intake of 30 students for each of the two programmes from January.
Dr Frances Barr, BSAVA's Academic Director, said: "Whilst we had only envisioned taking 30 new students onto each course this year, it quickly became clear that there is such a great appetite for this kind of accredited CPD in the profession right now. What a shame it would have been not to find a way to allow those ambitions to be fulfilled. So we are effectively going to run each programme twice in one year."
Quality control and sufficient student support is being met thanks to an overwhelming response from our teaching faculty and mentors. Dr Barr added: "BSAVA owes thanks to all those who lecture and work alongside our Certificate students. Without them we would not have been able to respond so quickly to this unprecedented demand".
The second programme will take place at two sites; BSAVA HQ in Gloucester, and the College of Animal Welfare in Huntingdon. Anyone who has not been able to take a place in the 2013 cohort will be offered priority registration for the 2014 in-take. For more information about BSAVA Certificates visit www.bsava.com or email administration@bsava.com.
New legislation will be introduced in the New Year making slaughterhouse CCTV a legal requirement in all areas where live animals are present, with unrestricted access to at least 90 days of footage for Official Veterinarians. The new law will come into force in the spring, with slaughterhouses allowed an adjustment period of up to six months.
The new legislation followed a public consultation which was overwhelmingly in favour of compulsory CCTV. Defra says that out of almost 4,000 respondents, more than 99% were supportive of the plans.
Environment Secretary Michael Gove said: "We have some of the highest animal welfare standards in the world and want to cement our status as a global leader by continuing to raise the bar.
"The reaction to this consultation highlights the strength of feeling among the public that all animals should be treated with the utmost respect at all stages of life and be subject to the highest possible welfare standards.
"These strong measures also provide a further demonstration to consumers around the world that as we leave the EU we continue to produce our food to the very highest standards."
BVA Senior Vice President Gudrun Ravetz said: "The mandatory installation of CCTV is a vital tool to ensure high standards of animal health, welfare and food safety in all slaughterhouses.
Official Veterinarians carry out an essential role in slaughterhouses by independently assessing and reporting breaches of animal welfare, and unrestricted access to CCTV footage will allow them to carry out this role even more effectively.
We have been campaigning for these measures for a number of years and it is reassuring to see such a high level of support for their implementation from industry and the public."
Heather Hancock, Chairman of the Food Standards Agency, said: "The Secretary of State’s decision to require CCTV in all slaughterhouses is a welcome step towards ensuring that animal welfare and hygiene standards are met across the meat industry.
"Last year, the FSA Board concluded that, without mandatory CCTV in slaughterhouses, we would see minimal further progress in businesses improving animal welfare or complying with official controls to protect public health.
"We look forward to working with the industry as CCTV plans are implemented, and to seeing public confidence rise as a result."
The government will now further discuss the details of bringing in the proposals and present draft legislation to Parliament as soon as Parliamentary time allows.
Photo: Lititz, Pennsylvania. Hoisting a slaughtered steer in Benjamin Lutz's slaughterhouse, 1942. Wikipedia.
During the 60 days before to 30 days after calving, dairy cows experience a dip in their natural immunity, leaving them especially vulnerable to important diseases such as mastitis2, metritis3 and retained placenta.4 With serious cost consequences and implications for cow welfare and productivity, this makes the transition period one of the most challenging yet vital periods for vets to manage with dairy clients.
Imrestor (pegbovigrastim injection) is a pegylated form of the naturally occurring protein cytokine, bovine Granulocyte Colony Stimulating Factor (bG-CSF). Elanco says it helps restore the cow’s natural defences by increasing the number and restoring the function of neutrophils, the primary type of white blood cell that recognizes and kills harmful bacteria.
Fiona Anderson, Technical Vet at Elanco, said: "It’s no secret that a successful transition period is vital for maximising productivity in the next lactation, yet we are still ‘firefighting’ common transition diseases like mastitis rather than focusing on their true cause."
"Vets are under increasing pressure to adopt a more proactive approach, not least to reduce the use of antibiotics in livestock but with few credible alternatives. This can be challenging in dairy herds, particularly around calving when cows are susceptible to multiple disease challenges while their defences are low. Imrestor helps to restore a cow’s own natural immunity and strengthen her ability to defend against infection by a range of mastitis pathogens – thus helping to protect the cow against mastitis when she needs it most."
Available in pre-filled, single-dose syringes, Imrestor is administered with two injections – one seven days prior to the anticipated date of calving and the other within 24 hours after calving – with neither injection requiring a withdrawal period.
Kingsley Baxendale, Ruminant Marketing Manager at Elanco Animal Health said: "It can be extremely frustrating for vets to see their dairy farmers struggling with the stress and hassle of dealing with increased numbers of sick cows during calving; they have enough to deal with at the moment. We’re delighted that Imrestor can provide vets with a tool to help decrease the negative consequences associated with immune-related diseases like mastitis and maximise their herds’ lactation potential."
As part of the launch of Imrestor, Elanco also announced its new 'Pledge To Protect' initiative to encourage vets and farmers to make a pledge symbolising their commitment to address immune suppression in their dairy cows.
The number of pledges will be tracked using a life-sized 2D cow model, pictured above. For each pledge, which can be made online or at events, Elanco will make a £5 donation to The Royal Agricultural Benevolent Institution (R.A.B.I), which supports farmers in difficulty. As a thank you for showing support, all pledgers will automatically be entered into a weekly prize draw.
To find out more about using Imrestor and how you can make your pledge, visit www.vital90days.co.uk.
Pfizer Animal Health's Equine Herpes Virus (EHV) vaccine (Duvaxyn EHV 1,4) has been rebranded Equip EHV 1,4).
Pfizer says that EHV is carried by most horses in the UK1 and can cause respiratory disease, abortion and more rarely neurological disease. However, it is the more common sub-clinical infections that pose the most apparent issue for the competition client, with the associated loss of performance and the potential effect on the health of the whole yard.
Once infected with EHV, a horse can harbour the virus throughout its life and potentially shed the disease to other animals without showing any outward signs. According to the company, vaccinating helps to minimise the severity of the disease itself and importantly, can also help to reduce the amount of infective virus that is shed to other in-contact horses.
Equip EHV 1,4 is given as a primary course of two vaccinations, 4-6 weeks apart followed by a single dose every six months. It can also be used as an aid in the control of EHV-1 abortion - pregnant mares should be vaccinated with a single dose during each of the 5th, 7th and 9th months of pregnancy.
For further information on Pfizer's EHV campaign, to obtain literature for your practice or to book a talk for your clients contact your Pfizer Account Manager or Pfizer Animal Health, Walton Oaks, Tadworth, Surrey KT20 7NS.
Reference
1. Eddington et al. Equine Vet. J. 1994; 26 (2): 140-142.
The webinars, which are free of charge, are:
The webinars join 'The gastrointestinal microbiome and its effects', which is already available for free viewing via The Webinar Vet.
Product Manager Kai Crawshaw said: “We’ve received excellent feedback on the webinars from those who have already viewed them through our Learning Alliance platform. We hope that by also making them available via The Webinar Vet, we will make them more easily accessible to a higher number of veterinary professionals keen to refresh their knowledge in these important areas.”
The Animalcare webinars can be viewed here: https://www.thewebinarvet.com/webinars/animalcare
The oral corticosteroid powder formulation was previously only available in 180g tubs.
Severe equine asthma, which was previously known as Recurrent Airway Obstruction (RAO), Chronic Obstructive Pulmonary Disease (COPD) or Heaves, can lead to airway neutrophil influx and excessive mucus production. Although it is generally managed by environmental measures to suppose triggering factors, it can be combined with corticosteroid therapy to control airway inflammation in more severe cases.
Alana McGlade BVMedSci BVM BVS MRCVS, Equine Business Manager, said: "Severe equine asthma is the most common cause of chronic coughing in mature horses. Attributed to a hypersensitivity to inhaled allergens and dust, clinical signs - such as inflammation of the airways - can be alleviated by Equisolon’s active ingredient prednisolone.
"Prednisolone has been shown to have positive effects on clinical signs, endoscopic evaluation, arterial blood gases and pulmonary function when used in conjunction with environmental changes to reduce a horse’s exposure to potential triggers.
"Previously, vets would have had to measure out the powder but the sachets make dosing more convenient. The sachets come in a box of 10, so each pack will treat one 300 kg horse for 10 days or one 600 kg horse for 5 days. As the sachets are pre-measured, horses get exactly the dose they need.”
Equisolon oral powder contains 33.3 mg/g of prednisolone and should be administered at 1 mg prednisolone per kg of body weight per day. Treatment can be repeated at 24 hour intervals during 10 consecutive days.
For more information visit www.dechra.co.uk
Alison has been an active member of the BSAVA since graduating from the University of Glasgow Veterinary School in 1991.
She works in small animal practice and has completed a residency in feline medicine at Liverpool University’s School of Veterinary Science, as well as a PhD in canine Bordetella bronchiseptica.
She has also spent two years working in industry.
Sheldon will stay on to support the BSAVA as Senior Vice President.
Alison says her priorities for her time in office are to develop more innovative materials across the Association's Education, Congress, and Publications arms, to beef up the digital offering, and to focus on mental heath and wellbeing in the profession.
Alison said: "I’ve been a passionate member of the BSAVA throughout my career and a volunteer for almost as long.
"As a working vet, I know first-hand the value of being part of a professional community: the importance of shared values, educational opportunities, and support shouldn’t be underestimated.
"We must remain focussed on the day-to-day challenges veterinary teams face, respond appropriately and at pace, and continue to explore new and effective ways to support our members.”
Animalcare says hydrocortisone aceponate is a potent, topical anti-inflammatory, proven to quickly relieve itchy and inflamed skin in dogs.
The new product is applied as a spray, designed to make it easy to target affected areas of skin.
Hydrocortisone Cutaneous Spray Solution is presented in a 76 ml size with a two-year shelf life, six months once opened.
Animalcare Product Manager Eleanor Workman Wright said: “Skin problems are extremely common in dogs.
"They can often cause great discomfort to dogs and concern to their owners.
"We believe that Hydrocortisone Cutaneous Spray Solution will be a useful addition to the range of treatment options currently available to vets as they consider the most appropriate care plan for their patients.”
Sue, an RCVS and European Specialist in Veterinary Dermatalogy and Senior Vice President of the European Society of Dermatology, says the failure to prioritise pain relief is having a "profound effect on the quality of life of both dogs and clients."
Sue is urging vets to think about the impact that pain has on both the dog and owner in cases of OE: "Otitis externa is painful, it’s debilitating, and the degree of discomfort is often underestimated by both the veterinary surgeon and by the client."
Sue also says vets should not underestimate the owner’s concern about pain in their dog. Owners recognise the clinical signs associated with the pain of OE and determine treatment success by their dog recovering from these distressing symptoms.
To help manage the pain associated with OE, Sue recommends a multi-modal approach: "In addition to systemic pain relief, which is really important, a potent topical steroid is really useful to reduce the inflammation inside that dog’s ear, and make it much more comfortable."
Sue also highlights OE treatments which are able to coat the ear canal and stay there long enough to treat the pathogens and provide sustained pain relief: "When you put it into the ear, Osurnia Gel coats the lining of the external ear canal which gives prolonged contact with the lining of the canal to help treat the pathogens inside that dog’s ear."
Elanco says that despite Osurnia entering the market two years ago, some vets are still saving it for difficult cases. Sue said: "Too many vets use this [Osurnia] as a second-line drug and it should be used as a first-line product on the first occasion the dog comes through the door."
To watch the full series of videos and to find out more from Sue Paterson on treating otitis externa in dogs, visit: www.Osurnia.co.uk
Sabrina joins Fran Taylor-Brown, Simon Bertram and head of service Tom Cardy.
Tom, a European and RCVS specialist in neurology, said Cave is now the biggest specialist-led neurology service in the South West:
“We are very pleased to have Sabrina join the neurology service at Cave, expanding our team to four European and RCVS-recognised specialists in veterinary neurology. This really sets Cave apart from our competitors.
“Sabrina’s arrival, in conjunction with the installation of our new state-of-the-art MRI scanner, means we can see most urgent neurology referrals within 24-48 hours in nearly all cases and increase the number of neurology cases we treat each day.”
Cave’s new £1.2m Phillips Ingenia 1.5T Evolution offers 50% faster scans at a far higher resolution than its previous MRI and shorter general anaesthetics for patients.
It also allows a more detailed and accurate diagnosis of complex neurological conditions.
Tom added: “The MRI scanner is one of the most advanced imaging modalities for the nervous system, providing millimetre-thick cross-sectional images of the brain and spinal cord which is essential for both accurate diagnosis and treatment.
“Having such advanced equipment and facilities plus four recognised specialists means all our clients and their pets will see a vet with the highest level of training in veterinary neurology.
“All of our specialists are happy to discuss challenging cases on the phone with our referring vets and Sabrina's skills and enthusiasm will continue to improve and diversify the service we offer.
https://cave-vet-specialists.co.uk
The outbreak, which was widely covered in the media, caused concern amongst cat owners.
The findings of an investigation found a link between high concentrations of trichothecene T-2/HT-2 mycotoxins (both poisonous substances, produced by fungi) in certain cat foods.
The first study, published in the Journal of Veterinary Internal Medicine, describes 580 cats recorded by the RVC’s database during the initial outbreak, the epidemiology of the cases and the link with mycotoxin exposure.
The cats presented with severe reductions in vital blood cells, including white blood cells responsible for fighting infection and platelets responsible for blood clotting.
The research recounts how analysis of these cats’ data – provided both by pet owners and vets - revealed three diets that had been consumed by the majority of affected cats and how this subsequently led to a UK wide recall in June 2021.
Examining the subsequent analysis of the feed samples and the discovery of mycotoxin contamination, which is known to be toxic to bone marrow, and thereby negatively impacting the production of key blood cells, the study concludes that mycotoxin contamination should be considered as the cause of the outbreak.
The second study examines 50 cats identified as having pancytopenia in more depth, providing a detailed picture of clinical findings to better understand the disease process in these cats affected by the outbreak.
Records and data of 50 of the affected cats were assessed to identify additional clinical signs which indicated contact with mycotoxins.
Following examination of the cats’ bone marrow, it was found that all cats suffered a marked toxic insult to their bone marrow.
From this, the study concluded that a differential diagnosis of mycotoxin-induced pancytopenia should be considered in cats presenting with pancytopenia.
Lead author of the research, Dr Barbara Glanemann, Senior Lecturer in Small Animal Medicine at the Royal Veterinary College and Co-head of the Small Animal Internal Medicine Service at the RVC’s Queen Mother Hospital for Animals, said:
“These pieces of research involved a great deal of work from many people (noted as authors and acknowledgements in the papers) and we really appreciate the teamwork involved, and the collaborative support we received.
“We know first-hand how much devastation and concern this outbreak caused for many cat owners across the country and so it is our hope that the studies will help people better understand what happened to cause this outbreak and can be used to not only provide some closure to those affected but also reduce the chances of something similar occurring in the future.”
Vet-AI's automated triage app offers instant advice to pet owners 24/7, early detection of health issues and advice as to whether they need to speak to a vet.
For the blinded test, which was conducted in April 2025, three UK veterinary surgeons reviewed the responses from Vet-AI, Gemini 2.0 and ChatGPT 4.0 to 48 simulated enquiries from owners.
The vets evaluated each on clinical accuracy, triage effectiveness and the subjective criteria of factuality, integrity, safety, empathy and readability.
Vet-AI’s Large Language Model (LLM) achieved an accuracy score of 81%, surpassing Gemini (69%) and ChatGPT (50%).
Vet-AI’s model also stopped triage at the correct point in 81% of cases according to the vets, compared with Gemini’s 75% and ChatGPT’s 56%.
Vet-AI’s tool also outperformed the leading LLMs on subjective measures, delivering more empathetic, thorough and factual responses to pet owners.
Samantha Webster, Chief Veterinary Officer at Vet-AI said: “These latest results are a significant milestone in the development of automated triage.
"We’re proving we can provide trustworthy online pet care by combining clinical and technical expertise.
"This tool can support the wider industry too, engaging more pet owners in the first step of vet care, ensuring their pets get the care they need - whether in practice or remotely.
"We know that an increasing percentage of the UK pet population is struggling to access veterinary care.
"Whilst AI will never replace a vet, the use of innovative technology can break down the barrier to access, leading to more pets getting the care they need, when they need it."
“With this level of clinical accuracy and technical innovation, we're helping to bring great pet care to more people. As well as helping to create more demand for vet services by making the triage of pets as accurate as possible,” said Paul Hallett, Vet-AI founder and exec chair.
https://www.vet-ai.com/automated-triage
Lamond Veterinary Clinic from Livingston, West Lothian has won the first ever Merial Charity Rounders Challenge.
The winning team of vets and vet nurses batted and fielded their way to victory in September's rounders tournament involving practices from the region.
Merial Territory Manager Caroline Fox said: "The winners received a shield acknowledging their sporting triumph. Everyone had a fun day and all proceeds raised from the event went to their chosen charity, the SSPCA."
She added: "Everyone enjoyed the event so much, we are already being asked to organise another tournament for next year."
If any practices would like to participate in future ‘Charity Rounders Challenges', please contact Caroline Fox on 07825624413 or email: caroline.fox@merial.com
The offer is timed to coincide with the expected increase in canine pruritis as the warmer weather leads to increased levels of common allergens such as pollen, dust mites and flea bites.
Each practice that buys five packs of Apoquel will get one free, subject to a minimum qualifying purchase.
Apoquel is a fast-acting oral therapy for the treatment of canine pruritus associated with allergic dermatitis.
Zoetis says its novel mechanism of action on the Janus Kinase (JAK) enzyme is specifically designed to target the pruritogenic and pro-inflammatory pathways involved in the itch cycle. This, says the company, allows effective reduction of allergic itch regardless of its cause as well as improvement of skin lesions associated with allergic skin diseases and atopic dermatitis.
For more information about the Apoquel Spring offer, contact your Zoetis account manager.